Company / Shareholders' Equity
Dare Bioscience, Inc. Shareholders' Equity History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$6.0M
FY2025
5-year range
-$94.3M / $38.8M
FY2021-FY2025
Trend
-19.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Dare Bioscience, Inc. reports negative total equity of -$6M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$6M in FY2025.
Declined from $11M to -$6M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Dare Bioscience, Inc.'s shareholders' equity has declined for 3 consecutive years.
- In FY2025, shareholders' equity decreased 19.1% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.0M | -19.1% |
| FY2024 | -$5.0M | -145.4% |
| FY2023 | $11.1M | -71.3% |
| FY2022 | $38.8M | +141.1% |
| FY2016 | -$94.3M | +0.0% |
| FY2015 | -$94.3M | -17.8% |
| FY2014 | -$80.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026